Two Neurodegenerative Disease Drugs Secure EMA's Coveted PRIME Designation
Executive Summary
What is claimed to be the first therapy targeting the underlying cause of Huntington’s disease and a gene therapy for Lorenzo’s Oil disease have become the latest investigational products to make it onto the European Medicines Agency’s priority medicines scheme.